Pilot Award Program SAC Incubator projects will foster the establishment of extramurally-funded, nationally-recognized centers of excellence in biomedical research with the potential to generate new strategic directions for the School of Medicine and Dentistry and the University. Funded projects will be innovative, multi-investigator projects with the potential to give new life to the overall scientific portfolio of the UR and keep the institution in the forefront of today's fast-paced and competitive scientific landscape. Each SAC Incubator proposal must involve a team of 3 or more co-principal investigators. A multi-PI leadership plan is required. New Request for Applications for SAC incubator grant Deadlines Letter of Intent/Initial application: November 2, 2015 (by 5:00 pm) Full Proposal Submission*: March 15, 2016 (by 5:00 pm) *Selected applicants will receive a notification of invitation to submit full proposals. Download the RFA on the SAC Incubator Program. SAC Incubator Awards Funded Incubator Project (awarded 7/1/2014): Project Title: “Intra-tissue refractive index shaping (IRIS) for customizing refractive correction.” PIs: Krystel Huxlin, Wayne Knox, and Jonathan Ellis. IRIS is a revolutionary approach to vision correction, which uses a femtosecond laser below the damage threshold of the corneal matrix or hydrogel lenses to alter their refractive index. We have made substantial progress on the proposed aims (summarized below), both in terms of technology development, and demonstrating safety, efficacy and long-term resilience of IRIS in the cat cornea. We are now poised to begin testing in human tissue this summer. Live human experiments/testing are being planned to begin 12 months from now. Regulatory consultants have been engaged and we have begun conversion to GLP and GCP systems in preparation for FDA submission. Funded Incubator Project (awarded 7/1/2015) : Project Title: “Novel approaches to overcome therapy resistance in prostate cancer" PIs: C. Chang, J. Krolewski Other key personnel: Y. Chen*, C. Fung, E. Guancial, O. Hyrien, F. Li, E. Messing, K. Nastiuk, D. Sahasrabudhe, Y. Sun, R. Wood, S. Yeh* The long-term goal is to build a research program (P01) focused on developing novel treatments for therapy resistant forms of human prostate cancer (PrCa). The program leverages the discovery – in the Chang lab –of ASC-J9, a curcumin derivative that degrades the androgen receptor (AR). ASC-J9 is particularly valuable because it can circumvent resistance to androgen deprivation therapy (ADT) as well as newer anti-androgen therapies. Individual projects extend the utility of ASC-J9 by investigating the mechanism and pre-clinical efficacy of combining this AR-targeting agent with non-AR therapies (radio-, cytokine directed- and chemotherapy) to treat therapy resistant PrCa.